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Background and purpose: The incidence of hospitalizations, treatment and
case fatality of ischaemic stroke were assessed utilizing a comprehensive multi-
national database to attempt to compare the healthcare systems in six Euro-
pean countries, aiming also to identify the limitations and make suggestions
for future improvements in the between-country comparisons.
Methods: National registers of hospital discharges for ischaemic stroke identi-
ﬁed by International Classiﬁcation of Diseases codes 433–434 (ICD-9) and code
I63 (ICD-10), medication purchases and mortality were linked at the patient
level in each of the participating countries and regions: Finland, Hungary, Italy,
the Netherlands, Scotland and Sweden. Patients with an index admission in 2007
were followed for 1 year.
Results: In all, 64 170 patients with a disease code for ischaemic stroke were
identiﬁed. The number of patients registered per 100 000 European standard
population ranged from 77 in Scotland to 407 in Hungary. Large diﬀerences
were observed in medication use. The age- and sex-adjusted all-cause case fatal-
ity amongst hospitalized patients at 1 year from stroke was highest in Hungary
at 31.0% (95% conﬁdence interval 30.5–31.5). Regional diﬀerences in age- and
sex-adjusted 1-year case fatality within countries were largest in Hungary (range
23.6%–37.6%) and smallest in the Netherlands (20.5%–27.3%).
Conclusions: It is feasible to link population-wide register data amongst Euro-
pean countries to describe incidence of hospitalizations, treatment patterns
and case fatality of ischaemic stroke on a national level. However, the cover-
age and validity of administrative register data for ischaemic stroke should be
developed further, and population-based and clinical stroke registers should be
created to allow better control of case mix.
Introduction
Trends in stroke mortality from the late 1960s to the
mid 1990s have shown considerable diﬀerences
between countries [1]. Low and declining mortality
rates have been observed in Western Europe whilst
already high stroke mortality has continued to
increase even further in Eastern Europe. Stroke inci-
dence is strongly age-dependent, and Europe has one
of the most rapidly ageing populations in the world.
Large diﬀerences in mortality along with scarcity of
data on treatment practices and outcomes of ischae-
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mic stroke in European countries indicate a need for
nationwide comparative databases as a ﬁrst step in
identifying explanations for diﬀerences.
Case fatality following stroke has been used in
hospital benchmarking as a measure of outcome in
several countries, including Canada, Finland, Den-
mark, Hungary, Italy, the Netherlands, Sweden, UK
and the USA [2,3]. International comparisons of out-
come for hospital benchmarking have been based
either on administrative national discharge registers or
data collected in a similar way from individual hospi-
tals in diﬀerent countries [2]. The latter studies are
typically based on a limited number of hospitals, and
thus their results may not be generalizable to stroke
care within or between countries. Studies based on
administrative databases include generic problems
such as diﬀerences in coding practice, lack of interna-
tionally standardized codes, and methodology [3]. A
major impediment in many countries for performing
nationwide benchmarking is the inability to link data
within and between diﬀerent national administrative
databases.
In the European Healthcare Outcomes, Perfor-
mance and Eﬃciency (EuroHOPE) study national
administrative databases were linked at the individ-
ual patient level. As there are diﬀerences between
European countries in healthcare systems, in levels
of prosperity and in sociocultural characteristics,
also diﬀerences in healthcare performance could be
assumed. For testing this hypothesis, hospitaliza-
tions, prevalence of comorbidities, treatment and
case fatality were assessed for ischaemic stroke
patients hospitalized in 2007 in six European coun-
tries and regions: Finland, Hungary, Italy (Lazio
Region and City of Turin), the Netherlands, Scot-
land and Sweden. The case fatality of ischaemic
stroke patients between regions in each country was
also compared. Limitations are identiﬁed and sugges-
tions are made for future improvements in between-
country comparisons.
Methods
In the EuroHOPE project retrospective observational
databases of stroke treatment episodes were created
using national administrative registers whilst exploit-
ing experiences from the Finnish Performance, Eﬀec-
tiveness and Costs of Treatment Episodes
(PERFECT) project [4–8]. Patients from the hospital
discharge registers of the six participating European
countries with admissions with a diagnostic code for
stroke between 1 January 2007 and 31 December 2007
were included. Patients were followed for 365 days
from the index admission.
Episode definition and register linkage
The treatment episode starts from the initial acute
hospital stay (i.e. index admission) with incident
stroke diagnosis, includes all continuous hospital
treatment and transfers of patients between hospitals,
and ends with the patient’s death during hospital stay,
discharge to home or discharge to a long-term care
facility such as a nursing home.
Stroke comprises three subtypes: ischaemic stroke,
intracerebral haemorrhage and subarachnoid haemor-
rhage, with ischaemic stroke being the most common,
at around 70%80% of all strokes [9].
In EuroHOPE International Classiﬁcation of Dis-
eases version 9 (ICD-9) discharge codes 433–434 and
ICD-10 code I63 were classiﬁed as ischaemic stroke,
431/I61 as intracerebral haemorrhage, 430/I60 as sub-
arachnoid haemorrhage and 436/I64 as undeﬁned
stroke. This study included only patients with ischae-
mic stroke; patients having also subsequent haemor-
rhagic stroke during the same hospital episode were
excluded. Additional exclusion criteria were prior
admission due to stroke in the hospital discharge reg-
ister (HDR) during the previous 365 days of index
admission; tourists, visitors or other residents with
incomplete national personal identiﬁcation numbers;
unknown place of residence and patients under
18 years of age.
Data on comorbidities were gathered for the pur-
pose of case mix adjustment from the primary and
secondary diagnoses of the country-speciﬁc HDR and
from medication purchases recorded in the prescribed
drug register for a period of 1 year before the index
admission. Data on medication purchases were also
gathered for the ﬁrst year after the index admission.
All-cause case fatality and date of death within 1 year
were recorded from the register of causes of death in
each participating country. Data on date of death and
medication purchase were linked with the HDR using
personal identiﬁcation numbers in all countries except
the Netherlands where deductive algorithms were used
[8].
The incidence of hospital admission, treatment and
outcome of ischaemic stroke
Crude incidence of hospital admission and incidence
of hospital admission adjusted by age and sex to the
European standard population [10] are reported per
100 000 population. Medication use was estimated
(using respective ATC codes) by the proportions of
patients purchasing, at least once during the year
before and year after the ischaemic stroke, the follow-
ing preventive medications: dipyridamol, clopidogrel,
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warfarin, antihypertensives (diuretics, angiotensin-
converting enzyme inhibitors, beta blockers), insulin
or other hypoglycaemic drugs, and statins. Data on
use of aspirin were not available as it is an over-the-
counter drug. Hospital-speciﬁc information on the
level of service provided (comprehensive stroke centre,
primary stroke centre or general ward) according to
the international classiﬁcation [11,12] was dependent
on whether our clinical experts in each country had
access to this information. Data on thrombolysis were
gathered from the procedure codes in the HDR
according to classiﬁcations used in each country. Out-
come was measured as all-cause case fatality within
30, 90 and 365 days of index hospitalization.
Statistical methods
Adjustment was made for age and sex when compar-
ing countries and regions. Based on the experiences in
the PERFECT project [4] the observed/expected
approach described by Ash et al. [13] was used. Spe-
ciﬁcally, the method uses logistic regression modelling
for risk adjustment. Indicators were produced at
national and at regional levels within the countries.
Regional information is based on patients’ place of
residence registered in the HDR. The regions within
each country have been deﬁned according to the
national legislation. All data were analysed using
Stata version 12 from StataCorp (College Station,
TX, USA).
A detailed description of the methods of the Euro-
HOPE stroke project is available online (www.euro-
hope.info).
Results
There were 64 170 admissions with a diagnostic code
for ischaemic stroke in the registers of the six coun-
tries during the year 2007. The incidence and baseline
characteristics of the patients in the participating
countries are shown in Table 1.
The most common comorbid diseases during the
previous year were hypertension, coronary artery dis-
ease, atrial ﬁbrillation, cancer and diabetes (Table 1).
Antithrombotic treatment (excluding aspirin) prior to
the ischaemic stroke was most common in Finland.
The proportion of patients treated at comprehensive
stroke centres, primary stroke centres and general hos-
pitals showed considerable variation amongst coun-
tries (Table 2). The proportion of patients who had a
record of being treated with thrombolysis was 3.5%
in Finland; there was lack of data on this treatment in
the other countries.
The age- and sex-adjusted case fatality rates at 30-
day, 90-day and 1-year follow-up are shown in
Table 2. Regional variation existed in the age- and
sex-adjusted 1-year case fatality (Fig. 1). The diﬀer-
ence between regions having lowest and highest case
fatality was 10.1 percentage points in Finland (from
15.9% to 26.0%), 14.0 (from 23.6% to 37.6%) in
Hungary, 10.2 (from 10.9% to 21.1%) in Italy, 6.8
(from 20.5% to 27.3%) in the Netherlands, 8.8 (from
24.6% to 33.4%) in Scotland and 9.0 (from 16.3% to
25.3%) in Sweden.
Discussion
EuroHOPE utilized a multinational patient level com-
prehensive database with nationwide coverage to eval-
uate how hospitalized ischaemic stroke patients are
treated within the healthcare system [14]. It is based
on administrative registers and is not population-
based, such as the WHO MONICA project [15]. Vali-
dation of the EuroHOPE data against medical record
review in each participating country and region would
have been optimal, but as resources were not available
to do this the validity of our approach was estimated
using previous methodological and epidemiological
data.
Validity of stroke diagnoses in the HDR and Causes of
Death Register
A Finnish validation study found a HDR diagnostic
sensitivity of 80% and positive predictive value of
82% for ischaemic stroke with comprehensive cover-
age in the Causes of Death Register [16]. In Sweden,
the positive predictive value for ﬁrst-ever strokes of
two administrative registers combined was 94% and
the sensitivity 92%, but data speciﬁc for ischaemic
stroke were not reported [17]. Completeness of hospi-
tal discharge records for stroke assessed against stroke
audit databases at national level for 2006–2009 data
for Scotland showed that only around 50% of inci-
dent ischaemic strokes were identiﬁed using the I63
code as a large proportion receive the I64 code of ill-
deﬁned stroke (Sarah Wild, personal communication).
To our knowledge, accuracy data of ischaemic stroke
diagnoses in the HDR are not available for the other
participating countries.
The sensitivity of the HDR depends on the hospi-
talization rate of stroke, for which estimates vary
amongst the participating countries (Table 3). Popula-
tion-based studies suggest that almost all stroke
patients are hospitalized in Finland, Hungary, Italy
and Sweden, but around 30% are treated in the com-
munity in the Netherlands and Scotland (Table 3)
© 2014 The Author(s). European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
286 A. MALMIVAARA ET AL.
[18]. Unlike the other countries with comprehensive
coverage and linkage of the HDR, in the Netherlands
a considerable proportion of hospitals do not partici-
pate in the Dutch HDR. The proportion of undeﬁned
stroke (ICD-10 I64) in the HDR was small in Finland
and Hungary but high in Italy (17.8%) and the Neth-
erlands (21.5%), and very high in Scotland (37.7%).
As a consequence, the incidence of ischaemic stroke in
these countries is underestimated and estimates of case
fatality may be biased. A potential source of bias is
misclassiﬁcation or miscoding of stroke subtypes.
Transient ischaemic attacks (TIAs) or ill-deﬁned
strokes were not included as coding practices with
regard to TIA and ill-deﬁned stroke might vary
between countries, and there is evidence that TIA
diagnoses and codifying TIAs with ischaemic stroke
are not accurate in administrative registries [19,20].
Ischaemic stroke patients having a previous stroke
more than 1 year before the hospital admission were
not excluded. This may have led to inclusion of more
than 10% of patients who have had an earlier stroke
[21,22].
The low incidence of hospitalizations in the Nether-
lands and Scotland, and the large proportion of un-
deﬁned strokes in the Netherlands, Scotland and
Italy, raise questions regarding comparability of
patients at baseline. In the Netherlands and Scotland
some of the patients with milder symptoms may have
been treated at home, and also elderly patients with
poor prognosis may have been treated conservatively
in nursing homes [18].
Validity of other variables
Scientiﬁc evidence on the accuracy of the HDR data
on comorbidities, medication use, stroke centre treat-
ment or thrombolysis are lacking in all the countries.
However, baseline data on comorbid conditions were
Table 1 Incidence and baseline characteristics of ischaemic stroke patients in six European countries: Finland, Hungary, Italy (Lazio Region
and City of Turin), the Netherlands, Scotland and Sweden during the year 2007
Finland Hungary Italy The Netherlands Scotland Sweden
Adult population 4 204 459 8 163 506 5 346 579 12 793 540 4 096 793 7 251 275
Ischaemic stroke hospitalizations 8735 34 148 9024 12 263 3591 19 065
N per 100 000 265 480 169 96 88 344
N per 100 000 European
standard population
190 407 145 97 77 218
Ischaemic stroke admissions of
all stroke codes registered (%)
78 87 66 59 46 76
Mean age, years 72.6 69.5 73.8 71.6 72.9 76.2
Female gender (%) 49.1 52.4 45.1 48.2 52.7 49.4
Hospital days within previous year 4.6 4.9 2.4 3.0 6.4 4.6
Patients with comorbid conditions (%)
Hypertension 70.9 76.5 65.4 77.2 NA 70.3
Coronary heart disease 9.9 13.3 6.9 3.6 NA 8.0
Atrial ﬁbrillation 9.1 4.5 3.7 2.7 NA 9.0
Cardiac failure 5.1 4.6 2.8 1.7 NA 5.6
Diabetes mellitus 20.0 21.7 23.2 19.6 NA 16.8
Peripheral artery disease 2.6 8.7 2.1 0.5 NA 0.9
Cancer 6.4 2.9 2.7 3.7 NA 3.2
COPD and asthma 13.0 14.9 17.6 19.3 NA 11.0
Dementia 5.0 2.8 1.3 1.3 NA 3.1
Depression 14.4 15.3 11.3 15.4 NA 17.9
Mental disorders 4.2 5.7 1.9 5.6 NA 3.2
Alcoholism 1.2 1.0 0.0 0.3 NA 0.8
Patients with medication purchases during 365 days prior to stroke (%)
Clopidogrel 3.4 8.5 4.1 NA NA 4.1
Dipyridamole 10.3 1.9 0.0 NA NA 4.9
Warfarin 15.1 0.6 2.8 NA NA 8.0
Diuretic 39.8 1.9 41.7 NA NA 45.3
Beta blocker 52.7 45.4 20.0 NA NA 46.8
ACE inhibitor 26.4 59.6 35.6 NA NA 24.0
Angiotensin receptor blocker 17.7 5.5 24.7 NA NA 13.4
Statin 33.6 30.8 28.4 NA NA 24.0
Insulin 7.7 5.5 5.9 NA NA 8.3
Other hypoglycaemic drugs 16.0 18.8 19.3 NA NA 11.7
NA, not available; COPD, chronic obstructive pulmonary disease; ACE, angiotensin-converting enzyme. Data are mean or %.
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collected by combining the HDR data with data on
purchase of medicines. The former seem to capture
the more severe conditions such as cancer or myocar-
dial infarctions, whilst the latter capture conditions
such as hypertension or diabetes which less often lead
to hospitalization and are poorly recorded in hospital
data. Nevertheless, only limited access to medication
purchase data from the Netherlands and from the
City of Turin in Italy was available, and no medica-
tion purchase data at all from Scotland. Despite these
shortcomings, prevalence rates of cardiovascular dis-
eases, atrial ﬁbrillation and diabetes at baseline as
estimated by our method are similar to those reported
for ischaemic stroke patients in population-based
studies [1,23].
Selection of patients
In order to assess the possible diﬀerences in selection
of patients to our database, our incidence data were
compared with those of population-based incidence
studies. Population-based stroke incidence studies
have reported age- and sex-speciﬁc ischaemic stroke
incidence rates for many of the participating countries
[9,18,24–29]. In addition, the World Health Organiza-
tion (WHO) has produced its own estimates for total
Table 2 Stroke centre classiﬁcation, medication and case fatality of patients admitted to a hospital due to ischaemic stroke in six European
countries and regions in 2007 (Italy: Lazio Region and City of Turin)
Finland Hungary Italy The Netherlands Scotland Sweden
Stroke centre classiﬁcation of the ﬁrst hospital episode (%)
Comprehensive stroke centre 38.9 46.5 0.0 NA 87.5 NA
Primary stroke centre 32.2 40.7 35.8 NA 3.8 NA
General hospital 28.9 12.8 64.2 NA 7.8 NA
Patients with medication purchases in 365 days after the stroke (%)
Clopidogrel 8.0 13.0 13.7 NA NA 6.3
Dipyridamole 35.3 2.7 0.1 NA NA 21.3
Warfarin 27.2 0.9a 7.3 NA NA 13.9
Diuretic 37.3 43.4 45.5 NA NA 47.7
Beta blocker 45.2 37.3 22.8 NA NA 46.6
ACE inhibitor 31.2 50.4 42.7 NA NA 34.6
Angiotensin receptor blocker 21.5 7.0 26.1 NA NA 14.9
Statin 55.4 32.7 43.0 NA NA 48.1
Insulin 7.2 5.1 8.2 NA NA 8.9
Other hypoglycaemic drugs 14.0 15.7 19.0 NA NA 11.0
All-cause case fatality, age and sex adjusted (95% CI)
30 day 10.2 (9.6–10.8) 16.3 (15.8–16.7) 7.5 (6.9–8.0) 12.4 (11.8–13.0) 13.2 (12.1–14.3) 9.3 (8.9–9.7)
90 day 14.5 (13.8–15.2) 22.6 (22.1–23.1) 10.7 (10.1–11.3) 16.7 (16.1–17.4) 19.0 (17.8–20.2) 13.3 (12.9–13.7)
365 day 20.7 (19.9–21.5) 31.0 (30.5–31.5) 16.0 (15.3–16.7) 23.4 (22.6–24.1) 28.2 (26.8–29.6) 20.1 (19.6–20.6)
NA, not available; ACE, angiotensin-converting enzyme. aData on dicoumarol, the prevalent oral anticoagulant in Hungary, are not available.
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Figure 1 Age- and sex-standardized case fatality during the ﬁrst year after incident ischaemic stroke in 2007 at diﬀerent regions of six
countries: Finland, Hungary, Italy (Lazio Region and City of Turin), the Netherlands, Scotland and Sweden.
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stroke incidence per age group [30]. As expected, is-
chaemic stroke incidence estimates were lower with
the EuroHOPE methodology than in the population-
based studies (Fig. 2). On the other hand the popula-
tion-based studies were conducted 20 years prior to
the present study, and ischaemic stroke incidence has
mostly declined since [9], e.g. in Finland at a rate of
2% per annum [31], although in the Netherlands the
incidence seems to have been rather stable over time
[32]. The ranking of the countries seems to be similar
in the previous studies, and the incidence rates in
Scotland and in the Netherlands are low in the Euro-
Table 3 Selection of patients to the EuroHOPE database  factors which may decrease the coverage of ischaemic stroke cases in the registers
of the EuroHOPE countries (percentages of cases)
Finland, % Hungary, % Italy, % The Netherlands, % Scotland, % Sweden, %
Stroke hospitalization rate for non-fatal cases 95 [22] 90a 87 [27] 60 62 84 [29]
Proportion of hospitalized patients registered
and linkable in the HDR
100 100 100 63 100 100
Sensitivity of ischaemic stroke coding in the
HDR for population-based ischaemic stroke
80 [16] NA NA NA 68 (LOT) NA
Positive predictive value of ischaemic stroke
coding in the HDR
82 [16] NA NA NA 95 NA
Proportion of undeﬁned stroke coding out of
all stroke diagnoses in the EuroHOPE database
0.4 3 18 22 38 8
HDR, hospital discharge register; NA, not available; LOT, based on comparison of data from hospital records and stroke register for the
Lothian region, 2010–2011. aExpert opinion of the EuroHOPE research group.
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Figure 2 Incidence of ischaemic stroke in subgroups of age and gender in Finland, Hungary, Italy (Lazio Region and City of Turin),
the Netherlands, Scotland and Sweden according to the WHO survey [30], population-based epidemiological studies [18,24–26,29] and
the EuroHOPE data.
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HOPE data as patients treated out of hospital were
not included in the present study. Based on this com-
parison, our method is expected to be reasonably
accurate and generalizable for national monitoring of
stroke (comparisons of regions within countries), and
applicable for international comparisons in all the
participating countries and regions except for Italy,
Scotland and the Netherlands.
Baseline characteristics and treatments
Deﬁcient reporting of comorbidity was found in Italy
(particularly in the City of Turin), the Netherlands
and Scotland due to incomplete reporting of second-
ary diagnoses in the hospital discharge data and lack
of comparable out-of-hospital medication data.
Nevertheless, our data suggest that there were marked
diﬀerences in prescription patterns between the coun-
tries (Table 2): warfarin, dipyridamole and statins
were recorded as being used in Finland and antihyper-
tensives and antidepressants in Sweden more often
than in other countries both before and after stroke,
and the use of preventive medications in general was
lowest in Hungary. However, data on warfarin use in
Hungary were not obtained.
There is evidence indicating that treatment in com-
prehensive stroke centres decreases case fatality
amongst ischaemic stroke patients [12]. A recent paper
describing data from six centres in France, Lithuania,
UK, Spain, Poland and Italy between 2004 and 2006
with follow-up for 1 year showed that better organiza-
tion of care was associated with improved survival
[33]. Unfortunately our data obviously underestimate
the proportion of patients obtaining stroke centre
treatment, which has also been considered an impor-
tant quality criterion [34]. Our experts from the
participating countries often did not have access to
hospital level information about treatment in stroke
centres. In addition, the coding of thrombolytic ther-
apy in our data was incomplete and severely underes-
timates the use of this treatment as has been found
also in earlier studies [6]. Other missing quality indica-
tors in all the countries include in-hospital care com-
ponents, such as use of imaging modalities and
rehabilitation. Recently, the European Stroke Organi-
zation issued recommendations for establishing stroke
care units and stroke centres [34]. It is recommended
to carry out a new survey to assess the current situa-
tion in Europe.
Case fatality
The large proportion of patients with diagnostic
code ‘undeﬁned stroke’ makes the comparison for
case fatality rate between Italy, the Netherlands and
Scotland and the other countries subject to bias.
Also, inability to fully adjust for case mix is a major
limitation of our study. It was not possible to adjust
for stroke baseline severity, which is known to be a
major predictor of outcome [35,36]. Signiﬁcant
national diﬀerences in baseline stroke severity might
exist, depending on primary and secondary preven-
tion intensity. For optimal case mix adjustment clini-
cal registries are needed [37]. One reason for
variability in outcome may also be related to the dif-
ferences in the gross domestic products, which has
to be further explored within the EuroHOPE study
[38].
The OECD performance data on age- and gender-
standardized 30-day case fatality for ischaemic stroke
in the year 2007 were in Finland, Hungary, Nether-
lands and Sweden 11.0%, 16.1%, 11.8% and 10.6%,
respectively (http://stats.oecd.org/). These mortality
rates are very similar to those found in the present
EuroHOPE study, where individual level analyses and
long-term follow-up was possible.
Standardized methods were employed to undertake
a detailed assessment of regional variation within
countries in case fatality after ischaemic stroke
amongst hospitalized patients. Wide variation was
found between regions in all the participating coun-
tries with the highest variation in Hungary. The small-
est variation observed in the Netherlands may be
partly due to the relatively large size of the regions.
Health policy and scientific implications
In order to make pertinent choices on how to improve
eﬀectiveness of treatment, data are needed on how
patients are treated and what their outcomes are in
real world settings [7,39]. The EuroHOPE database
was modelled in line with the PERFECT database,
which is used in Finland to evaluate performance at
regional and hospital level in treatment of major dis-
eases, including stroke [4–6,12,40]. The main beneﬁts
of these register studies reﬂect their ability to utilize
existing databases to capture the patient population
beyond the acute phase, in this case for a year or until
death.
Despite uncertainties in the EuroHOPE analysis,
three major conclusions can be drawn. First, the inci-
dence and 1-year case fatality of patients admitted
with ischaemic stroke seems to be higher in Hungary
than in the other countries. However, the impact of
the healthcare for this higher case fatality cannot be
ascertained as the register data do not allow adjust-
ment for baseline severity. Whilst Hungarian patients
have higher incidence, they probably also have
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more severe stroke when arriving at hospitals, and the
ﬁndings of EuroHOPE suggest national measures
directed both on primary and secondary prevention
and to the development of clinical pathways for stroke
care. Secondly, there are large diﬀerences in the 1-year
case fatality after admissions to hospital with an is-
chaemic stroke code between regions within all the
EuroHOPE countries. Thirdly, detailed data on case
mix and treatment practices is currently not compre-
hensively available in administrative registries on is-
chaemic stroke. Therefore, additional studies are
required to investigate further the apparent diﬀerences
in outcome. Case fatality in patients with ischaemic
stroke was <20% in three regions in Finland and two
regions in Sweden. This may reﬂect diﬀerences in case
deﬁnition and ascertainment, and in patient character-
istics, but substantive variation in the extent to which
evidence-based practice has been implemented cannot
be excluded. A wider adoption of clinician-led analysis
of the nature and quality of care delivered to the pop-
ulation of stroke patients is urged. The Scottish
Stroke Care Audit is an example of how this can be
achieved (http://www.strokeaudit.scot.nhs.uk/
index.html).
The validity of administrative register data for
ischaemic stroke should be developed further to facili-
tate international comparisons. It would be appropri-
ate to create population-based stroke registers linked
to mortality and other data in order to provide more
detailed information about case mix. The long-term
goal of the EuroHOPE project is to provide regularly
updated comparative data on clinical processes and
outcomes of patients, including reasons for diﬀerences
between countries and regions, and ultimately linking
quality of treatment and costs. Besides continuing the
international collaboration, national eﬀorts to identify
best practices and to assess the reasons behind regio-
nal diﬀerences in outcomes are recommended.
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